BLIS Technologies Ltd
NZX:BLT

Watchlist Manager
BLIS Technologies Ltd Logo
BLIS Technologies Ltd
NZX:BLT
Watchlist
Price: 0.015 NZD -6.25% Market Closed
Market Cap: 19.2m NZD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one BLT stock under the Base Case scenario is hidden NZD. Compared to the current market price of 0.015 NZD, BLIS Technologies Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BLT Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

1.5
P/S
P/S
Price to Sales
1.5
vs History
90
vs Industry
63
Median 3Y
2.3
Median 5Y
4.8
Industry
2.5
More Details
22.9
P/E
P/E
Price to Earnings
22.9
vs History
38
vs Industry
36
Median 3Y
-18.3
Median 5Y
11.6
Industry
21.1
More Details
10.7
P/OCF
P/OCF
Price to OCF
10.7
vs History
61
vs Industry
38
Median 3Y
11.4
Median 5Y
19.5
Industry
16.2
More Details
17.2
P/FCFE
P/FCFE
Price to FCFE
17.2
vs History
44
vs Industry
23
Median 3Y
17
Median 5Y
16
Industry
23.7
More Details
1.6
P/B
P/B
Price to Book Value
1.6
vs History
92
vs Industry
48
Median 3Y
2.4
Median 5Y
3.2
Industry
2.1
More Details
0.8
EV/S
EV/S
Enterprise Value to Sales
0.8
vs History
92
vs Industry
78
Median 3Y
1.6
Median 5Y
3.8
Industry
2.6
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.1
More Details
20.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
20.2
vs History
30
vs Industry
45
Median 3Y
-14.5
Median 5Y
5.6
Industry
12.4
More Details
20.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
20.2
vs History
30
vs Industry
45
Median 3Y
-14.5
Median 5Y
5.6
Industry
15.7
More Details
5.5
EV/OCF
EV/OCF
Enterprise Value to OCF
5.5
vs History
63
vs Industry
48
Median 3Y
6.4
Median 5Y
12.7
Industry
14.4
More Details
7.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
7.5
vs History
53
vs Industry
35
Median 3Y
9.5
Median 5Y
9.5
Industry
17.1
More Details
3.1
EV/IC
EV/IC
Enterprise Value to IC
3.1
vs History
88
vs Industry
25
Median 3Y
4
Median 5Y
6.1
Industry
1.8
More Details

Multiples Across Competitors

BLT Competitors Multiples
BLIS Technologies Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
NZ
BLIS Technologies Ltd
NZX:BLT
19.2m NZD 1.5 22.9 20.2 20.2
US
Eli Lilly and Co
NYSE:LLY
753.6B USD 15.4 67.8 36.4 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
365.7B USD 4.1 16.8 12.3 16.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.3 18.3 12.7 14.5
CH
Roche Holding AG
SIX:ROG
208.5B CHF 3.4 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
188.1B CHF 4.4 18.3 10.8 14.4
UK
AstraZeneca PLC
LSE:AZN
157.3B GBP 3.9 27.8 130.6 196.9
US
Merck & Co Inc
NYSE:MRK
198.3B USD 3.1 11.4 8.5 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
137.8B USD 2.2 17.5 7.5 10.6
P/E Multiple
Earnings Growth PEG
NZ
BLIS Technologies Ltd
NZX:BLT
Average P/E: 25.1
22.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
67.8
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.8
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.3
18%
1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
18.3
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
27.8
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.4
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.5
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NZ
BLIS Technologies Ltd
NZX:BLT
Average EV/EBITDA: 396
20.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.4
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
13%
1
CH
Roche Holding AG
SIX:ROG
9.5
5%
1.9
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.6
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.5
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NZ
BLIS Technologies Ltd
NZX:BLT
Average EV/EBIT: 1 699.2
20.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.8
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.1
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
14.5
14%
1
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.8
CH
Novartis AG
SIX:NOVN
14.4
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
196.9
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.3
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.6
10%
1.1

See Also

Summary
BLT intrinsic value, competitors valuation, and company profile.
DCF Valuation
BLT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BLT stock valuation using valuation multiples.
Wall Street Estimates
BLT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BLT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 264,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.